基石藥業(02616.HK)治療肺癌藥物達總生存期研究終點
基石藥業(02616.HK)公布,舒格利單抗一線治療轉移性(IV期)非小細胞肺癌(NSCLC)的註冊性臨床研究GEMSTONE-302達到總生存期(OS)的研究終點。
研究顯示,舒格利單抗聯合化療可顯著延長患者的OS並具有臨床意義。基於此前GEMSTONE-302研究報道的優異的無進展生存期(PFS)數據,中國國家藥監局已於2021年12月批准舒格利單抗的新藥上市申請,用於聯合化療一線治療轉移性鱗狀和非鱗狀NSCLC患者。
OS等詳細的研究數據將在近期召開的國際學術會議中公布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.